NCT00215566

A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP733 in Patients With Irritable Bowel Syndrome With Constipation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (planned)
• Sponsor: Dynogen Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety, tolerability and pharmacodynamics of the investigational drug DDP733 in treating subjects with IBS-c. A placebo control will be utilized.

Conditions

• Irritable Bowel Syndrome With Constipation
• Irritable Bowel Syndrome

Interventions

Type	Name	Description
DRUG	DDP733

Timeline

• Start date: 2005-09-01
• First posted: 2005-09-22
• Last updated: 2007-05-28

Locations

15 sites across 1 country: Canada